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strides in improving pediatrics-
focused therapeutics. At the same time, there is still a relative paucity
of clinical pharmacology data in regard to the pediatric population.
Here, we review past and current legislative efforts in the United
States, highlight current limitations, and suggest future practice and
policy initiatives to optimize pediatric drug therapy.
Background
In response to mounting concerns regarding the safety and
efﬁcacy of medications used in pediatric populations, the Best
Pharmaceuticals for Children Act (BPCA) was enacted in 2002.1
The purpose of the BPCA was to promote clinical trials of
pharmaceuticals in children that would generate safety and
efﬁcacy data. The ultimate goal was pediatric-use approval for
more pharmaceuticals and expansion of current drug labeling.1,2
Additional legislation, in the form of the Pediatric Research Equity
Act (PREA), passed in 2003.3 The BPCA and PREA were reauthor-
ized in 2007 and made permanent in 2012 as part of the Food and
Drug Administration Safety and Innovation Act (FDASIA).1–4 Since
its inception, the BPCA has stimulated pediatrics-focused clinical
pharmacology research and led to hundreds of drug labeling
revisions.5 Despite these major strides, there remains a paucity
of data regarding the safe and effective use of medication in
pediatric populations. Here, we highlight the existing challenges
in optimizing pediatric drug therapy and offer potential solutions.Current Challenges in Pediatrics-Focused Drug Research
One of the major challenges in pediatric drug research is the
conduct of clinical trials in children. It has been established that the
pharmacokinetics and pharmacodynamics of drugs often differ
between children and adults. Children are also in a dynamic state of
growth and development and drug response and toxicity may differx.doi.org/10.1016/j.curtheres.2013.05.001
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ail address: maryannmazer@gmail.com (M. Mazer-Amirshahi).signiﬁcantly within pediatric age groups.2 At the same time, there are
ethical and practical concerns when studying pharmaceuticals in
pediatric populations, such as the complexities of obtaining consent
or analyzing small-volume blood samples. As such, the majority of
pharmaceuticals are prescribed to children in an “off label”manner.2,5
Before the late 1990s, there was little incentive for pharma-
ceutical manufacturers to conduct clinical trials in pediatric
populations. In 1997, the Food and Drug Administration Modern-
ization Act offered manufacturers an additional six months of
market exclusivity for conducting pediatrics-focused studies.2,6
Depending upon sales, an exclusivity extension could translate
into an additional $500 million in revenue for each drug pursued.6
This ﬁnancial incentive has stimulated pediatrics-focused clinical
trials and led to an increase in drug approvals for pediatric use. On
the other hand, manufacturers may perform trials of medications
with limited utility in pediatric populations to reap the beneﬁts
of the longer exclusivity for adult sales. In addition, trials involving
children often occur late in the life cycle of a drug, after it has been
on the market many years. Most pediatrics-focused trials are
performed using medications that have an adult indication; few
trials are performed to test novel therapies for pediatrics-speciﬁc
diseases. As such, these trials have limited beneﬁts for children,
which was not the intention of the legislation.6
Another major area of focus is to ensure appropriate phar-
maceutical labeling. Even when a particular medication has
pediatrics-speciﬁc data available in the labeling, it does not always
provide clear guidance for the prescriber. It is often unclear what
ages the drug is formally approved for and in many instances the
speciﬁc age range is not listed in the indications section of the
package insert. Approved pediatrics-speciﬁc dosing information, if
available, is listed in another section of the label. Finally, the
results of pediatrics-focused studies that have been performed
may be listed in yet another section, under special populations.
The BPCA has done a great deal to stimulate labeling revisions
for pediatrics use, yet there is often a signiﬁcant lag time between
when data becomes available and formal labeling revisions take
place.7 Years may elapse between when a speciﬁc toxicity is noted
and the drug label is amended. In addition, many pharmaceuticals
undergo postmarketing revisions regarding appropriate dosing
(most often these are dose reductions due to safety concerns).
Another shortcoming is that many drug references (for example,
the Physicians’ Desk Reference [www.pdr.net]) are based on
information found in the package insert, which may be outdated.n open access article under the CC BY-NC-SA license
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do not consult multiple references when routinely prescribing
medication.7
In addition to safety concerns, efﬁcacy is an important factor
when prescribing pharmaceuticals for pediatric populations.2 Even
though there has been an increase in the number of pediatric
pharmaceutical trials performed, there is still a relative paucity of
efﬁcacy data in this population. It has been demonstrated that the
results of negative clinical trials are generally less likely to be
published.5,6 Even if the results of a negative trial are published,
there may be a substantial lag time until this information is
disseminated to providers. As a result, pediatric patients may be
continuously exposed to a medication from which they may not
derive any therapeutic beneﬁt. At the same time, patients, their
families, and the health care system will continue to pay for
medications that may not be effective. This is further compounded
by the potential for adverse effects associated with unnecessary
medication use.Potential Solutions
During the past 2 decades, there have been major advances in
pediatric clinical pharmacology, yet there is still much work to be
done. Legislative efforts must continue to be supported by pro-
viders, industry, the Food and Drug Administration, and patient
advocacy groups. Major progress was made in this area when,
in 2012, FDASIA permanently reauthorized the BPCA and PREA.
In addition, FDASIA strengthened Food and Drug Administration
authority pertaining to pediatric clinical trials and promotes
studies in underserved populations, speciﬁcally neonates.4 Future
legislation should expand on current efforts and address short-
comings, such as focusing on pediatric-speciﬁc diseases that may
not have adult counterparts and unbiased reporting of clinical trial
data. At this time, the true inﬂuence of FDASIA has yet to be
determined and stakeholders must be vigilant in continuously
evaluating current efforts and promoting future legislative change.
The pharmaceutical labeling format for pediatrics should be
re-evaluated. The age groups a medication is formally approved for
should be explicitly stated in package inserts. Data from pediatrics-
focused studies should be clearly outlined and experience from
pediatrics-speciﬁc studies should be clearly differentiated in the
label from what is formally approved. Consideration should be
given to consolidating pediatric clinical pharmacology data into
1 speciﬁc section of the package insert, so that providers do nothave to go to multiple sections to ﬁnd data. Making drug labeling
clearer can promote safer prescribing practices.
Another major area to focus on is dissemination of information.
With regard to toxicity data, providers and parents should be
encouraged to report adverse drug events to the MedWatch
program, which will facilitate labeling revisions. Current informa-
tion technology platforms can facilitate the reporting process.
Because formal labeling changes may take a signiﬁcant amount
of time, efforts should be made to provide updates when an
adverse event is reported. Information can be disseminated
through a variety of methods, including journals, continuing
medical education programs, and Internet-based updates. In
addition, these venues may also be used to disseminate the
ﬁndings of pediatrics-focused studies, even if they are negative.
There have also been efforts to require manufacturers to report
their ﬁndings to peer-reviewed journals, which will limit the
prescribing of medication that has not demonstrated efﬁcacy in
pediatric populations.Conclusions
There has been a notable increase in pediatrics-focused phar-
macology data in response to legislation; however, additional
policy and practice steps need to be taken to ensure the safe and
effective use of medications in pediatric populations.
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